| Today's Top Story |  |  | | - Paladin might raise $56.7 million bid to take over Afexa
Paladin Labs said it will enhance a $56.7 million acquisition offer for Afexa Life Sciences if the latter's two shareholder-rights plans, or "poison pills," are removed. Paladin intends to ask the Alberta Security Commission at a hearing today to cease-trade Afexa's defensive tactic. "Should Paladin choose to increase their offer, we would invite them to further amend their offer at the same time to include a minimum tender condition so that they will only acquire control of Afexa if a majority of our shareholders [other than Paladin] support their bid," said Afexa Chairman William White. Winnipeg Free Press (Manitoba)/The Canadian Press (9/22)        | The Business Platinum Card® from American Express OPEN
Spending power for your business. Premium benefits for you.
Access a portfolio of 30+ premium benefits, including:
• Complimentary Airport Club Access
• Annual $200 Airline Fee Credit for any airline
• Built-in upgrades at FINE HOTELS & RESORTS
Business Platinum Card
APPLY NOW |
  - Working group discusses ethical boundaries of transgenic animals
Transgenic and chimeric animals are important for medical research, but the topic is little-discussed, leaving it open to misinterpretation, writes Martin Bobrow, professor emeritus of medical genetics at the University of Cambridge. Bobrow chairs the U.K. Academy of Medical Sciences working group on animals containing human material. The group found three scenarios that should be subject to strict oversight: substituting an animal's brain cells with human cells in a way that might give the animal humanlike cognitive capacity; implanting human-derived reproductive cells in an animal if there is a possibility of fertilization; and creating animals that resemble humans in certain aspects of their appearance or behavior. The Scientist online (free registration) (9/21) - U.K. experts find gene linked to motor neuron disease
U.K. scientists reported in the journal Neuron that they identified a gene mutation on chromosome 9 that appears to be responsible for motor neuron disease among Finnish patients and a Welsh family with a history of the condition. They hope the finding could pave the way for a blood test that can help pinpoint patients at risk for the disease and lead to treatments. BBC (9/21)  | LET’S GO DESIGN: Episode #4
In this episode of SolidWorks’ interactive web series, host Jeremy Luchini starts designing the chassis of the Hot Rod Baby Buggy using weldment features and sketch techniques. He also visits a metal fabrication shop to learn about methods that will help in building our project. Watch the new episode now at LetsGoDesign.tv |
 - NIH awards $143.8M in pioneer program grants
The NIH awarded $143.8 million under its Pioneer, New Innovator, and Transformative Research Projects program for research the agency deems innovative and high-risk. "The awards are intended to catalyze giant leaps forward for any area of biomedical research, allowing investigators to go in entirely new directions," said James Anderson, director of the Division of Program Coordination, Planning and Strategic Initiatives. Projects include developing new molecular tools for protein sequencing, mapping intracellular molecular pathways of toxicity, and control of gene expression and embryonic development. GenomeWeb Daily News (9/20) - CEO: Bristol remains strictly focused on prescription drugs
Bristol-Myers Squibb is 100% committed to the prescription-drug business and is willing to use about $10 billion in cash to expand its portfolio through midsize deals, said CEO Lamberto Andreotti at the Pharmaceutical Strategic Alliances Conference. He said Yervoy, a recently approved melanoma drug, "continues to do well." Reuters (9/22) - Acetylon begins study of drug candidate for multiple myeloma
Acetylon Pharmaceuticals initiated a Phase I-IIa clinical study of ACY-1215, a drug candidate for relapsed and relapsed-refractory multiple myeloma. Phase I tests the class 2 histone deacetylase inhibitor as a treatment alone and in combination with standard therapies. In Phase IIa, researchers will evaluate the cancer's response to the drug. Mass High Tech (Boston) (9/22)  | Despite being a backbone enterprise application, Enterprise Resource Planning is often misunderstood. In this guide from Focus, top experts provide their suggestions and recommendations to guide you through your evaluation of the best choices. Unravel the complexities of ERP once and for all to make an informed buying decision by downloading this free white paper. |
| Industrial & Environmental | | | | - Report: Defense Dept.'s clean-energy push will save lives, money
The Department of Defense is aggressively seeking clean-energy technologies, including advanced biofuels, in a bid to cut its dependence on oil, according to a report from Pew Charitable Trusts. "As one of the largest energy consumers in the world, the Department of Defense has the ability to help shape America's energy future," said Phyllis Cuttino, director of the Pew Clean Energy Program. "DOD's efforts to harness clean energy will save lives, save money and enhance the nation's energy and economic future," Cuttino added. San Jose Mercury News (Calif.) (free registration) (9/21) | News from BIO | | | | - Join the leaders of the biotech industry in Shanghai
At BIO China, Oct. 12 and 13, you'll have unprecedented opportunities to meet the leaders of China's most innovative biotech companies, many of whom have not attended conferences outside of China. Hear from speakers and panelists with insights into regulatory issues, intellectual property, clinical trials, manufacturing and product distribution in China. The conference also will feature one-on-one partnering meetings, company presentations, networking opportunities and an exhibit hall. Register now.
| SmartQuote | | | |  | It is absurd to divide people into good and bad. People are either charming or tedious."
--Oscar Wilde,
Irish writer and poet  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, September 22, 2011
- Wednesday, September 21, 2011
- Tuesday, September 20, 2011
- Monday, September 19, 2011
- Friday, September 16, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment